ArticleDiscover oncology2025
Pan-cancer analysis and validation of NT5DC2: emphasizing its prognostic significance and immunological role in TNBC.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
background5'-Nucleotidase Domain Containing 2 (NT5DC2), a member of the cNT5-II family that catalyzes nucleotide hydrolysis, plays a critical role in tumor initiation and progression. This study aims to elucidate the role of NT5DC2 across multiple cancers and to confirm its oncogenic significance in triple-negative breast cancer (TNBC).
methodsNT5DC2 expression patterns were analyzed across multiple databases to evaluate its diagnostic and prognostic value in various cancers. Immune correlation analyses were performed using ESTIMATE and CIBERSORT algorithms. KEGG pathway enrichment analysis was used to explore NT5DC2-associated molecular pathways. In TNBC, comprehensive bioinformatics approaches, including gene expression profiling, single-cell RNA sequencing, immune infiltration analysis, and gene set enrichment analysis (GSEA), were employed. Additionally, in vitro experiments were conducted to validate the oncogenic role of NT5DC2 in TNBC.
resultsHigh NT5DC2 expression was associated with poor prognosis and demonstrated significant clinical diagnostic value across several cancer types. In TNBC, NT5DC2 was found to be highly expressed and correlated with adverse outcomes. Single-cell RNA sequencing revealed that NT5DC2 is predominantly expressed in epithelial cells and may regulate immune cell behavior through the MIF signaling pathway. Enrichment and immune infiltration analyses further indicated that NT5DC2 is strongly associated with an immunosuppressive tumor microenvironment (TME). In vitro experiments showed that NT5DC2 knockdown significantly suppressed TNBC cell growth, whereas its overexpression exerted opposing effects, highlighting its therapeutic potential.
conclusionThis study identifies NT5DC2 as an oncogene with broad clinical relevance across multiple cancers. In TNBC, NT5DC2 contributes to an immunosuppressive microenvironment and represents a promising diagnostic marker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.